Canada’s generic GLP-1 highlights patent disparity with US
The approval of the first generic semaglutide for weight loss in Canada last week highlights key differences in patent regulation between Canada and the US, where the market-leading GLP-1 medication will...To view the full article, register now.
Already a subscriber? Click here to view full article